HELPER T CELL SUBPOPULATION ACTIVITIES IN HIV DISEASE

HIV 疾病中的辅助 T 细胞亚群活动

• 批准号: 6309280
• 负责人: GAILEN D. MARSHALL
• 金额: $ 1.51万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6309280
• 关键词: AIDS therapy; HIV infections; cell population study; clinical research; drug screening /evaluation; helper T lymphocyte; human subject; human therapy evaluation; immunoglobulin E; immunotherapy; interleukin 10; interleukin 4; pathologic process; respiratory disorder; respiratory disorder chemotherapy; rhinitis

A major complication of HIV disease is worsening respiratory conditions, which are often of allergic origin. This is a pilot study to identify prevalence of IgE-mediated respiratory correlated with HIV seroconversion and disease progression, and to test the safety of a standard allergen immunotherapy regimen in these HIV+ patients. Four patients have been enrolled in the study, and one has completed the study. These subjects have a history of severe perennial allergic rhinitis poorly responsive to medical therapy. They started weekly AIT and were monitored for CD4 populations, viral load and in vitro cytokine production. Results showed CD4 counts remained stable and plasma viral load remained undetectable. The in vitro tetanus-induced IFNg levels increased while IL-4 and IL-10 levels remained relatively unchanged. Clinical response has been remarkable, with symptom scores demising and need for regular medications no longer necessary. These data suggest that AIT may have utility in selected HIV+ patients and support the need for a larger controlled trial to establish which HIV+ patients might be expected to benefit from this therapy.

艾滋病毒疾病的主要并发症正在加剧呼吸系统疾病，通常是过敏性的。 这是一项试点研究，旨在确定IgE介导的呼吸道患病率与HIV血清转化和疾病进展相关，并测试这些HIV+患者中标准过敏原免疫疗法方案的安全性。该研究已入学四名患者，其中一名已经完成了这项研究。 这些受试者有严重多年生过敏性鼻炎的病史，对药物治疗的反应不佳。 他们每周开始AIT，并接受了CD4群体，病毒载荷和体外细胞因子产生的监测。 结果表明，CD4计数保持稳定，血浆病毒负荷仍然无法检测到。 体外破伤风诱导的IFNG水平升高，而IL-4和IL-10水平保持相对不变。 临床反应是显着的，症状得分降低了，不再需要常规药物。 这些数据表明，AIT可能在选定的HIV+患者中具有效用，并支持对更大的对照试验的需求，以确定可能会从这种疗法中受益于哪些HIV+患者。